金陵藥業(000919.SZ):擬取得東昇藥業不低於55%的股權
格隆匯12月6日丨金陵藥業(000919.SZ)公佈,公司與洪荷芳、柯善治、柯元立、柯善慧、艾德凱騰和東昇藥業於2021年12月3日簽署了《框架協議》,公司擬通過增資及股權受讓的方式取得東昇藥業不低於55%的股權;艾德凱騰擬通過增資方式取得東昇藥業10%的股權。
公司醫藥板塊經過多年發展,形成了包含藥品研發、生產、銷售為一體的醫藥製造全產業鏈佈局。公司擬通過增資及股權受讓的方式取得東昇藥業不低於55%的股權,符合公司“醫藥和醫康養護兩個平台建設,實現產業規模化發展的戰略要求;有利於聚焦公司原有優勢領域,謀求醫藥製造產業鏈上游資源整合,提升資源配置效率,夯實醫藥產業發展根基。有利於推動科研、原料、製劑及產業化的深度融合,達成戰略合作聚合效應 1+1 大於 2。有利於助力新藥研發,提高研發項目篩選空間,走創新驅動內生增長之路,提升核心技術能力,推動公司醫藥工業板塊高質量發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.